{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:40:05Z","timestamp":1782474005725,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011676","name":"Elekta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ZonMW IMDI\/LSH-TKI Foundation","award":["104006004"],"award-info":[{"award-number":["104006004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To describe the development and first outcomes of the Utrecht Prostate Cohort (UPC): the first \u2018trials within cohorts\u2019 (TwiCs) platform for prostate cancer (PCa).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All non-metastasized, histologically proven PCa patients who are planned to receive standard of care are eligible for inclusion in UPC. Patients provide informed consent for the\u00a0collection of clinical and technical patient data, physician-reported outcomes, and patient-reported outcomes (PROs) up to 10\u00a0years post-treatment. Additionally, patients may provide broad consent for future randomization for experimental-intervention trials (TwiCs). Changes in PROs (EPIC-26 questionnaire domains) of the participants who received standard of care were analyzed using Wilcoxon signed-rank tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In two\u00a0years, 626 patients were enrolled, 503 (80.4%) of whom provided broad consent for future randomization. Among these, 293 (46.8%) patients underwent magnetic resonance-guided adaptive radiotherapy (MRgRT), 116 (18.5%) CT-guided external beam radiation therapy (EBRT), 109 (17.4%) robot-assisted radical prostatectomy (RARP), and 65 (10.4%) patients opted for active surveillance. Patients treated with MRgRT and CT-guided EBRT showed a transient but significant decline in urinary irritative\/obstructive and bowel domain scores at 1-month follow-up. RARP patients showed a significant deterioration of urinary incontinence domain scores between baseline and all follow-up moments and significant improvement of urinary irritative\/obstructive domain scores between baseline and 9- and 12-month follow-up. All radical treatment groups showed a significant decline in sexual domain scores during follow-up. Active surveillance patients showed no significant deterioration over time in all domains.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The first results from the UPC study show distinct differences in PROs between treatment options for PCa.<\/jats:p>\n                <jats:p>Registration No.: NCT04228211.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-022-04092-2","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T13:05:41Z","timestamp":1658408741000},"page":"2205-2212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating \u2018trials within cohorts\u2019 (TwiCs) for the evaluation of interventions for prostate cancer"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct04228211","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-5195","authenticated-orcid":false,"given":"Frederik R.","family":"Teunissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Willigenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm H. E.","family":"van Melick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"Verkooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem R. N.","family":"van der Voort van Zyp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"4092_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4092_CR2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/nejmoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415\u20131424. https:\/\/doi.org\/10.1056\/nejmoa1606220","journal-title":"N Engl J Med"},{"key":"4092_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.radonc.2016.04.014","volume":"119","author":"AJ McPartlin","year":"2016","unstructured":"McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C et al (2016) MRI-guided prostate adaptive radiotherapy \u2013 a systematic reviewMRI-linac and prostate motion review. Radiother Oncol 119:371\u2013380. https:\/\/doi.org\/10.1016\/j.radonc.2016.04.014","journal-title":"Radiother Oncol"},{"key":"4092_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01510-w","author":"F Alongi","year":"2020","unstructured":"Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L et al (2020) 1.5 T MR guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol. https:\/\/doi.org\/10.1186\/s13014-020-01510-w","journal-title":"Radiat Oncol"},{"key":"4092_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.eururo.2018.01.001","volume":"74","author":"HG van der Poel","year":"2018","unstructured":"van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM et al (2018) Focal therapy in primary localised prostate cancer: the European association of urology position in 2018. Eur Urol 74:84\u201391. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.001","journal-title":"Eur Urol"},{"key":"4092_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1056\/nejmp1005843","volume":"363","author":"RC Young","year":"2010","unstructured":"Young RC (2010) Cancer clinical trials \u2014 a chronic but curable crisis. N Engl J Med 363:306\u2013309. https:\/\/doi.org\/10.1056\/nejmp1005843","journal-title":"N Engl J Med"},{"key":"4092_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","volume":"326","author":"F Song","year":"2003","unstructured":"Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 326:472\u2013475. https:\/\/doi.org\/10.1136\/bmj.326.7387.472","journal-title":"Br Med J"},{"key":"4092_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1023-4","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J (2015) A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. https:\/\/doi.org\/10.1186\/s13063-015-1023-4","journal-title":"Trials"},{"key":"4092_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2633","volume":"350","author":"P Sedgwick","year":"2015","unstructured":"Sedgwick P (2015) Controlled trials: allocation concealment, random allocation, and blinding. BMJ 350:h2633. https:\/\/doi.org\/10.1136\/bmj.h2633","journal-title":"BMJ"},{"key":"4092_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/bmj.c1066","volume":"340","author":"C Relton","year":"2010","unstructured":"Relton C, Torgerson D, O\u2019Cathain A, Nicholl J (2010) Rethinking pragmatic randomised controlled trials: introducing the \u201ccohort multiple randomised controlled trial\u201d design. BMJ 340:963\u2013967. https:\/\/doi.org\/10.1136\/bmj.c1066","journal-title":"BMJ"},{"key":"4092_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/eDe.0000000000000435","volume":"27","author":"DA Young-Afat","year":"2016","unstructured":"Young-Afat DA, Verkooijen HAM, Van Gils CH, Van Der Velden JM, Burbach JP, Elias SG et al (2016) Staged-informed consent in the cohort multiple randomized controlled trial design. Epidemiology 27:389\u2013392. https:\/\/doi.org\/10.1097\/eDe.0000000000000435","journal-title":"Epidemiology"},{"key":"4092_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ije\/dyw050","volume":"46","author":"JM van der Velden","year":"2017","unstructured":"van der Velden JM, Verkooijen HM, Ayoung-Afat D, Burbach JPM, van Vulpen M, Relton C et al (2017) The cohort multiple randomized controlled trial design: a valid and efficient alternative to pragmatic trials? Int J Epidemiol 46:96\u2013102. https:\/\/doi.org\/10.1093\/ije\/dyw050","journal-title":"Int J Epidemiol"},{"key":"4092_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","volume":"76","author":"KM Szymanski","year":"2010","unstructured":"Szymanski KM, Wei JT, Dunn RL, Sanda MG (2010) Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 76:1245\u20131250. https:\/\/doi.org\/10.1016\/j.urology.2010.01.027","journal-title":"Urology"},{"key":"4092_CR14","doi-asserted-by":"publisher","DOI":"10.2001\/6136\/001","author":"P Fayers","year":"2001","unstructured":"Fayers P, Aaronson N, Bjordal K (2001) EORTC QLQ-C30 scoring manual. Eortc. https:\/\/doi.org\/10.2001\/6136\/001","journal-title":"Eortc"},{"key":"4092_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pe\u00f1 BM (1999) Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319\u2013326. https:\/\/doi.org\/10.1038\/sj.ijir.3900472","journal-title":"Int J Impot Res"},{"key":"4092_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"4092_CR17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ, O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al (1992) The American urological association symptom index for benign prostatic hyperplasia. J Urol 148:1549\u20131557. https:\/\/doi.org\/10.1016\/S0022-5347(17)36966-5","journal-title":"J Urol"},{"key":"4092_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x","journal-title":"Acta Psychiatr Scand"},{"key":"4092_CR19","unstructured":"Tuomi K, Ilmarinen J, Jahkola A, Katajarinne L, Tulkki A (1998) Work Ability Index. 2nd revised edn. Finnish Inst Occup Health, Helsinki"},{"key":"4092_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","volume":"85","author":"TA Skolarus","year":"2015","unstructured":"Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS et al (2015) Minimally important difference for the expanded prostate cancer index composite short form. Urology 85:101\u2013105. https:\/\/doi.org\/10.1016\/j.urology.2014.08.044","journal-title":"Urology"},{"key":"4092_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.eururo.2014.08.075","volume":"67","author":"NE Martin","year":"2015","unstructured":"Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A et al (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67:460\u2013467. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.075","journal-title":"Eur Urol"},{"key":"4092_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00059","author":"HM Verkooijen","year":"2017","unstructured":"Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M et al (2017) R-IDEAL: a framework for systematic clinical evaluation of technical innovations in radiation oncology. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2017.00059","journal-title":"Front Oncol"},{"key":"4092_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jama.2019.20675","volume":"323","author":"KE Hoffman","year":"2020","unstructured":"Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA et al (2020) Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA - J Am Med Assoc 323:149\u2013163. https:\/\/doi.org\/10.1001\/jama.2019.20675","journal-title":"JAMA - J Am Med Assoc"},{"key":"4092_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3503","author":"CG Mazariego","year":"2020","unstructured":"Mazariego CG, Egger S, King MT, Juraskova I, Woo H, Berry M et al (2020) Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. BMJ. https:\/\/doi.org\/10.1136\/bmj.m3503","journal-title":"BMJ"},{"key":"4092_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.eururo.2017.06.035","volume":"72","author":"M Lardas","year":"2017","unstructured":"Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T et al (2017) Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review. Eur Urol 72:869\u2013885. https:\/\/doi.org\/10.1016\/j.eururo.2017.06.035","journal-title":"Eur Urol"},{"key":"4092_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(18)30780-0","volume":"20","author":"A Downing","year":"2019","unstructured":"Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E et al (2019) Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. Lancet Oncol 20:436\u2013447. https:\/\/doi.org\/10.1016\/S1470-2045(18)30780-0","journal-title":"Lancet Oncol"},{"key":"4092_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.phro.2021.09.002","volume":"20","author":"FR Teunissen","year":"2021","unstructured":"Teunissen FR, Wortel RC, Hes J, Willigenburg T, de Groot-van Breugel EN, de Boer JCJ et al (2021) Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for preservation of erectile function in prostate cancer patients. Phys Imaging Radiat Oncol 20:5\u201310. https:\/\/doi.org\/10.1016\/j.phro.2021.09.002","journal-title":"Phys Imaging Radiat Oncol"},{"key":"4092_CR28","unstructured":"EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT). ClinicalTrials.gov identifier: NCT04861194. Updated August 25, 2021. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04861194 Accessed 5 Feb 2022"},{"key":"4092_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1740774517746620","volume":"15","author":"SYH Kim","year":"2018","unstructured":"Kim SYH, Flory J, Relton C (2018) Ethics and practice of trials within cohorts: an emerging pragmatic trial design. Clin Trials 15:9\u201316. https:\/\/doi.org\/10.1177\/1740774517746620","journal-title":"Clin Trials"},{"key":"4092_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.10.015","author":"DA Young-Afat","year":"2021","unstructured":"Young-Afat DA, Gal R, Gerlich S, Burbach JPM, van der Velden JM, van den Bongard DHJG et al (2021) Oncology patients were found to understand and accept the trials within cohorts design. J Clin Epidemiol. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.10.015","journal-title":"J Clin Epidemiol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04092-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-022-04092-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04092-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T21:11:47Z","timestamp":1661893907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-022-04092-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["4092"],"URL":"https:\/\/doi.org\/10.1007\/s00345-022-04092-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"10 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HV receives research funding from Elekta. The remaining authors declare no potential competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received approval from the Institutional Review and Ethics Board of the University Medical Center Utrecht, the Netherlands and the was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent for participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}